Skip to main content

Table 1 Pancreatic cancer (PaC) incidence, Pancreas/Body weight (Wt) percent ratio and metastasis

From: Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in KrasG12D/+ mice

 

PaC N/tot

Pancreas/Body Wt%

Metastasis N/tot PaC

Ctr

1/12

1.3 ± 0.5

1/1

Diab1

9/12

3.3 ± 1.3***

8/9

Diab + FL1

3/12

1.6 ± 1.0†††

1/3

Ctr + FL

1/9

1.4 ± 0.5

1/1

STZ-non-Diab

1/9

1.3 ± 0.4

0/1

  1. Cumulative incidence of PaC and Pancreas/Body weight (Wt) percent ratio in control (Ctr), diabetic (Diab), Diab treated with FL-926-16 (Diab+FL), Ctr treated with FL-926-16 (Ctr + FL) and streptozotocin-treated non-diabetic (STZ-non-Diab) KCM mice at the end of the study (16 weeks of diabetes, 22 weeks of age1). The number of KCM mice with metastasis (liver and or lung) on the total number of PaC cases is also shown. KCM = LSL-KrasG12D/+; Pdx-1-Cre; MITO; N/tot = number of cases/total number of mice; N/tot PaC = number of cases/total number of PaC. PaC (ductal adenocarcinoma) and hepatic and/or lung metastasis were confirmed by histology. ***P < 0.001 or **P < 0.01 vs Ctr; †††P < 0.001 or †P < 0.05 vs Diab. Statistical significance between groups for Pancreas/Body Weight percent ratio was calculated using one-way ANOVA followed by the Student-Newman-Keuls test for multiple comparisons. Statistical significance for PaC rate was assessed using the Chi-squared test and Fisher’s exact test
  2. 1 Except for three Diab and one Diab + FL mice, which were killed 5 and 3 weeks, respectively, before the end of the study